Cell Biology, Genetics, Immunity, Inflammation, and Pathology Practice Flashcards

Cellular Biology and Function

• Basic Definition and Overview of Cells:

  • The cell is the fundamental structural, functional, and biological unit of all living organisms.

  • Human cellular composition: The adult human body consists of approximately $37 \text{ trillion}$ cells ($37 \times 10^{12}$ cells).

  • Diversity: There are over $200$ distinct cell types within the human body, each specialized for specific functions.

  • Physical Scale: Most human cells range between $10\text{--}30\,\mu\text{m}$ in diameter.

  • Extreme Cell Length: Neurons represent the longest cells in the human body, with single axonal extensions exceeding $3\,\text{ft}$ in length.

• Cellular Lifespans:

  • White Blood Cells (Leukocytes): Shortest-lived cells, ranging from a few hours to several days depending on subtype and immune activation state.

  • Skin Cells (Epithelial Cells): Turn over every $2\text{--}3\,\text{weeks}$.

  • Red Blood Cells (Erythrocytes): Circulate for approximately $12\,\text{days}$ (or up to $120\,\text{days}$ in standard physiological turnover).

  • Brain Neurons: Longest-lived cells; specific cerebral neurons persist across an individual's entire lifetime.

• Cellular Communication and Organelle Mechanics:

  • Red Blood Cell Production: Bone marrow functions as a metabolic factory, producing approximately $2 \times 10^6\,\text{new red blood cells/s}$.

  • Mitochondria Density: Individual cells contain hundreds to thousands of mitochondria depending on cellular metabolic demands.

  • Cellular Signaling: Cells transmit biochemical signals to coordinate physiological functions across tissue networks.

  • Apoptosis: Built-in programmed cell death mechanism executed to remove aged, damaged, or unneeded cells without releasing damaging intracellular content into surrounding tissue.

• Essential Cell Structures and Organelle Functions:

  • Cellular Membrane:

  • Functions as a selectively permeable barrier maintaining homeostasis.

  • Composed of a phospholipid bilayer containing embedded transport proteins and signaling receptors.

  • Receptors facilitate signal transduction, influencing cellular activity in response to external stimuli.

  • Loss of membrane integrity results in the leakage of intracellular enzymes and inflammatory chemical mediators.

  • Nucleus: Directs cellular activity, houses genetic material (DNA), and regulates transcription and replication.

  • Cytoplasm: Fluid-filled intracellular matrix containing cytosol, organelles, and cytoskeleton elements where metabolic chemical reactions occur.

  • Ribosomes: Protein-synthesizing structures that translate mRNA scripts into functional peptide chains.

  • Endoplasmic Reticulum (ER):

  • Rough ER: Studded with ribosomes; synthesizes and processes proteins destined for membranes or secretion.

  • Smooth ER: Synthesizes lipids, metabolizes carbohydrates, and detoxifies chemicals and drugs.

  • Mitochondria: Cellular powerhouses; generate adenosine triphosphate (ATP) via aerobic cellular respiration.

  • Golgi Complex: Modifies, sorts, packages, and routes proteins and lipids arriving from the endoplasmic reticulum.

  • Lysosomes: Membrane-bound digestive organelles containing hydrolytic enzymes to break down cellular waste, debris, and foreign particles.

Principles of Genetics and Inheritance Patterns

• Fundamental Genetic Terminology:

  • Genes: Basic physical and functional units of heredity; specific nucleotide sequences of DNA encoding molecular products (proteins or RNA molecules).

  • Genetics: The study of heredity, gene function, and variation in living organisms.

  • Chromosomes: Highly organized nuclear structures composed of tightly wound chromatin (DNA and histones).

  • DNA (Deoxyribonucleic Acid): The double-stranded helical molecule containing the genetic code for cellular structure and function.

  • Genetic Testing: Laboratory analysis of human DNA, RNA, chromosomes, or proteins to detect heritable or acquired disease-related genotypes, mutations, or karyotypes.

  • Congenital Disorders: Disorders or structural anomalies present at birth, resulting from inherited genetic mutations, chromosomal aberrations, or environmental developmental factors.

• Chromosomal Organization and Karyotype:

  • Humans possess $23\,\text{pairs}$ of chromosomes (total of $46$ chromosomes).

  • Autosomes: $22\,\text{pairs}$ of non-sex chromosomes.

  • Sex Chromosomes: The $23\text{rd}\,\text{pair}$, determining biological sex:

  • Female Genotype: $XX$

  • Male Genotype: $XY$

• Classification and Characteristics of Genetic Disorders:

  • Autosomal Dominant Disorders:

  • Mutation Pattern: Single mutant allele on a non-sex chromosome (autosomes $1\text{--}22$).

  • Inheritance Mechanics: Single copy of the mutant allele from one affected parent is sufficient to cause disease expression.

  • Distribution: Affects males and females with equal frequency.

  • Offspring Inheritance Risk: $50\%$ ($1$ in $2$) chance for each child born to an affected parent.

  • Homozygosity Outcome: Inheriting two mutated alleles is rare and typically lethal during the neonatal period.

  • Clinical Examples: Huntington's disease, Marfan syndrome, Neurofibromatosis, Familial hypercholesterolemia, Adult polycystic kidney disease.

  • Autosomal Recessive Disorders:

  • Mutation Pattern: Homozygous mutation in both copies of a gene on an autosome.

  • Inheritance Mechanics: Both parents must be heterozygous carriers (asymptomatic carriers) and pass the mutant allele to offspring.

  • Distribution: Affects males and females with equal frequency.

  • Offspring Probability (Carrier Parent $Tt \times Tt$):

    • Affected ($tt$): $25\%$

    • Carrier ($Tt$): $50\%$

    • Unaffected/Not Carrier ($TT$): $25\%$

    • Phenotypically Normal ($TT$ or $Tt$): $75\%$

  • Clinical Examples: Cystic fibrosis, Sickle cell anemia, Phenylketonuria (PKU), Tay-Sachs disease.

  • X-Linked Dominant Disorders:

  • Mutation Pattern: Mutation in a gene on the X chromosome.

  • Inheritance Mechanics: One copy of the mutation on the X chromosome causes disease.

  • Distribution: Females are affected more frequently than males; males often display more severe or lethal clinical symptoms due to hemizygosity.

  • Transmission Risk:

    • Affected Mother ($X^D X$): $50\%$ chance of passing the condition to each son and daughter.

    • Affected Father ($X^D Y$): Passes the allele to $100\%$ of daughters (all affected) and $0\%$ of sons (sons inherit Y chromosome).

  • Clinical Examples: Fragile X syndrome, Rett syndrome.

  • X-Linked Recessive Disorders:

  • Mutation Pattern: Mutation in a gene on the X chromosome.

  • Inheritance Mechanics: Requires two mutated alleles in females ($X^r X^r$) but only one mutated allele in males ($X^r Y$).

  • Distribution: Affects males almost exclusively; females act as asymptomatic carriers ($X^R X^r$).

  • Transmission Risk:

    • Carrier Mother ($X^R X^r$): $50\%$ chance of affected sons, $50\%$ chance of carrier daughters.

    • Affected Father ($X^r Y$): $100\%$ of daughters become carriers; $0\%$ of sons are affected.

  • Clinical Examples: Hemophilia A, Duchenne's muscular dystrophy, Red-green color blindness.

  • Multifactorial Disorders:

  • Cause: Polygenic interactions (multiple genes) combined with environmental influences.

  • Inheritance Pattern: Does not follow classic Mendelian inheritance rules; shows familial clustering.

  • Recurrence Risk: Typically $5\text{--}25\%$ depending on family degree and external risk factors.

  • Clinical Examples: Type 2 diabetes mellitus, Coronary heart disease, Cleft lip and palate, Schizophrenia.

  • Chromosomal Disorders:

  • Etiology: Abnormal distribution, loss, addition, or structural translocation of entire chromosomes or chromosomal segments during meiosis.

  • Definitions:

    • Monosomy: Absence of one chromosome from a normal pair ($2n - 1$).

    • Trisomy: Presence of three copies of a chromosome instead of a pair ($2n + 1$).

  • Risk Factor: Advanced maternal age significantly increases non-disjunction rates during oogenesis.

  • Recurrence Risk: Typically spontaneous with low familial recurrence ($<1\%$).

  • Clinical Examples: Down syndrome (Trisomy 21), Turner syndrome ($XO$ monosomy), Klinefelter syndrome ($XXY$ trisomy).

• Punnett Square Mathematical Demonstrations:

  • Scenario 1: Autosomal Dominant Condition ($H$ = mutant allele, $h$ = normal allele)

  • Cross: Father ($Hh$ - affected) $\times$ Mother ($hh$ - unaffected)

  • Offspring Genotypes: $2\,Hh$ : $2\,hh$

  • Probability of Affected Child ($Hh$): $50\%$

  • Probability of Unaffected Child ($hh$): $50\%$

  • Scenario 2: Autosomal Recessive Carrier Cross ($T$ = normal allele, $t$ = mutant allele)

  • Cross: Father ($Tt$ - carrier) $\times$ Mother ($Tt$ - carrier)

  • Offspring Genotypes: $1\,TT$ : $2\,Tt$ : $1\,tt$

  • Probability of Affected Child ($tt$): $25\%$

  • Probability of Carrier Child ($Tt$): $50\%$

  • Probability of Phenotypically Normal Child ($TT$ or $Tt$): $75\%$

  • Probability of Non-Carrier Child ($TT$): $25\%$

  • Scenario 3: Phenylketonuria (PKU) Clinical Case

  • Both parents are unaffected carriers ($Tt$) of PKU.

  • Affected infant genotype: $tt$

  • Recurrence risk for subsequent offspring: $25\%$

  • Carrier probability for unaffected siblings: $50\%$

• Differentiating Infectious vs. Genetic Carrier States:

  • Infectious Disease Carrier: An individual harboring a pathogenic organism (e.g., Hepatitis B) who can transmit the pathogen to others while showing variable clinical signs.

  • Genetic Carrier: An asymptomatic individual carrying one copy of a recessive mutated gene on an autosome or X chromosome who can pass that gene mutation to biological offspring.

• Nursing Responsibilities in Genomics:

  • Pathophysiological Understanding: Recognizing the underlying genetic etiology of non-communicable chronic conditions.

  • Pharmacogenomics and Medication Safety: Accounting for gene variations that alter drug metabolism, therapeutic efficacy, and toxicity profiles.

  • Risk Assessment: Gathering detailed family health histories to identify hereditary risk factors.

  • Patient Education and Guidance: Interpreting diagnostic tests, explaining inheritance risks, and clarifying medical options.

  • Holistic and Ethical Support: Navigating complex ethical decisions, genetic testing disclosures, and emotional distress surrounding hereditary diagnoses.

Immune System Organization and Response

• Lines of Defense:

  • First Line of Defense (Nonspecific Protection):

  • Mechanical barriers preventing pathogen entry: Unbroken skin and mucous membranes.

  • Secretions containing antimicrobial substances: Saliva, tears (lysozyme), gastric secretions (hydrochloric acid), mucus, and flushing actions of tears and urine.

  • Second Line of Defense (Nonspecific Protection):

  • Phagocytosis: Cellular engulfment of pathogens by specialized white blood cells.

  • Inflammation: Vascular and cellular response to tissue injury or pathogen entry.

  • Interferons: Antiviral proteins produced by virus-infected leukocytes to protect uninfected host cells.

  • Third Line of Defense (Specific Adaptive Protection):

  • Mediated by lymphocytes ($T$ cells and $B$ cells).

  • Involves production of antigen-specific antibodies and cell-mediated cytotoxicity.

  • Characterized by immunologic memory following initial antigen exposure.

• Anatomical and Cellular Components of the Immune System:

  • White Blood Cells (Leukocytes): Circulating effector cells executing cellular defense.

  • Antibodies (Immunoglobulins): Proteins synthesized by plasma cells that bind to specific foreign antigens.

  • Lymphatic System: Vessels, nodes, and lymphoid tissue filtering interstitial fluid and facilitating antigen presentation.

  • Bone Marrow: Primary site of hematopoiesis; maturation site for $B$ lymphocytes.

  • Thymus: Primary lymphoid organ site for $T$ lymphocyte differentiation and maturation.

  • Spleen: Secondary lymphoid organ filtering blood-borne pathogens and damaged red blood cells.

  • Skin and Mucous Membranes: Physical surfaces preventing pathogen colonization and invasion.

  • Complement System: Cascade of circulating plasma proteins that enhance phagocytosis, induce lysis, and promote inflammation.

• Innate versus Adaptive Immunity:

  • Innate (Nonspecific) Immunity:

  • Bloodborne/Vascular Defense:

    • Complement Cascade (Alternative Pathway activation).

    • Phagocytic Leukocytes:

    1. Neutrophils: Early responders to bacterial infection.

    2. Macrophages: Differentiated tissue monocytes performing sustained phagocytosis.

    3. Basophils: Granulocytes releasing histamine in acute inflammation.

    4. Eosinophils: Defense against parasitic infections and active in allergic reactions.

    5. Natural Killer (NK) Cells: Cytotoxic cells targeting tumor cells and virus-infected cells without prior sensitization.

  • Physical and Chemical Barriers: Skin, mucous membranes, saliva, tear/urine flushing, stomach acid.

  • Adaptive (Specific) Immunity:

  • T-Cell Immunity (Cell-Mediated):

    • Mediated by $T$ lymphocytes processed in the thymus.

    • Subtypes:

    1. Helper $T$ Cells ($CD4^+$): Direct immune response via cytokine secretion.

    2. Cytotoxic $T$ Cells ($CD8^+$): Destroy virus-infected, damaged, or transformed host cells.

    3. Suppressor/Regulatory $T$ Cells: Down-regulate immune activation to maintain self-tolerance.

  • B-Cell Immunity (Humoral Immunity):

    • Antigen activation triggers differentiation of lymphoblasts into:

    1. Plasma Cells: Produce specific antibodies targeting antigens; triggers Classical Complement Cascade.

    2. Memory $B$ Cells: Persist long-term to launch accelerated secondary immune responses upon re-exposure.

• Key Features of the Immune System:

  • Self vs. Non-Self Recognition: Differentiates autologous host cellular markers (MHC/HLA) from foreign antigenic targets.

  • Specificity and Memory: Tailors exact targeted molecular defenses and forms permanent cellular memory.

  • Tissue Repair Assistance: Cleans necrotic cellular debris to initiate tissue healing.

  • Immune Surveillance: Identifies and destroys malignant or dysplastic host cells.

  • Antibody Titers: Diagnostic blood tests measuring circulating antibody concentration to evaluate adaptive immunity levels.

  • Herd Immunity: Phenomenon where population-wide vaccination or immunity reduces total pathogen transmission, protecting susceptible non-immune individuals.

Inflammation Physiology, Mediators, and Pharmacotherapy

• Fundamental Physiology of Inflammation:

  • Definition: Inflammation is a protective, localized response of vascularized tissue to injury, destruction, or infection.

  • Nomenclature: Conditions involving acute or chronic inflammation are designated by the suffix -itis (e.g., appendicitis, carditis).

  • Distinction from Infection: Inflammation is a non-specific physiological defense mechanism. Infection (invasion by micro-organisms) is one specific cause of inflammation.

• Causes of Inflammation:

  • Direct Physical Damage: Cuts, abrasions, lacerations, sprains, blunt force trauma.

  • Caustic Chemical Exposure: Acids, alkalis, drain cleaners, chemical irritants.

  • Ischemia or Infarction: Loss of regional arterial blood flow resulting in cellular hypoxia and necrosis.

  • Allergic Reactions: Hypersensitivity reactions triggering mast cell degranulation.

  • Temperature Extremes: Thermal burns, frostbite.

  • Foreign Bodies: Splinters, glass, surgical material.

  • Pathogenic Infection: Bacteria, viruses, fungi, parasites.

• Capillary Fluid Dynamics: Normal vs. Inflammatory State:

  • Normal Microvascular Exchange:

  • Arterial End: Hydrostatic pressure exceeds plasma osmotic pressure, driving fluid, electrolytes, oxygen, and nutrients into interstitial fluid.

  • Venous End: Plasma colloid osmotic pressure (mediated by albumin) exceeds hydrostatic pressure, pulling water, carbon dioxide, and metabolic wastes back into capillaries.

  • Inflammatory Fluid Shift:

  • Injury induces localized arterial vasodilation, increasing hydrostatic pressure.

  • Capillary permeability increases as endothelial cells contract, creating large inter-endothelial gaps.

  • Protein-rich fluid (plasma proteins, albumin, globulins, fibrinogen) and leukocytes escape into the interstitial space, forming inflammatory exudate.

• Sequence of Events in Acute Inflammation:

  1. Tissue injury triggers damaged cells to release bradykinin.

  2. Bradykinin stimulates local nociceptors (pain receptors).

  3. Bradykinin and tissue damage trigger mast cell and basophil degranulation, releasing histamine.

  4. Bradykinin and histamine induce local arteriolar vasodilation, increasing regional blood supply (hyperemia).

  5. Capillary endothelial permeability increases significantly.

  6. Bacteria or foreign substances enter damaged interstitial spaces.

  7. Leukocytes undergo marginalization, rolling, and chemotaxis toward chemical signal gradients.

  8. Neutrophils arrive first and perform active phagocytosis of pathogens and debris.

  9. Monocytes exit blood vessels, transform into tissue macrophages, and execute sustained phagocytosis.

• Chemical Mediators of Inflammation:

  • Histamine (Source: Mast cell granules): Causes immediate vasodilation and increased capillary permeability to form exudate.

  • Chemotactic Factors (Source: Mast cell granules): Chemically attract neutrophils to the site of injury.

  • Platelet-Activating Factor [PAF] (Source: Cell membranes of platelets): Activates neutrophils and induces platelet aggregation.

  • Cytokines / Interleukins / Lymphokines (Source: $T$ Lymphocytes, Macrophages): Increase synthesis of liver plasma proteins, elevate ESR, induce fever, promote chemotaxis and leukocytosis.

  • Leukotrienes (Source: Synthesized from arachidonic acid in mast cells): Mediate secondary delayed inflammation response, vasodilation, increased capillary permeability, and leukocyte chemotaxis.

  • Prostaglandins [PGs] (Source: Synthesized from arachidonic acid in mast cells): Induce vasodilation, increased capillary permeability, direct pain sensitization, fever, and potentiate histamine release.

  • Kinins / Bradykinin (Source: Activation of plasma kininogen cascade): Induces vasodilation, increased capillary permeability, severe pain sensation, and neutrophil chemotaxis.

  • Complement System (Source: Activation of plasma protein cascade): Triggers vasodilation, capillary permeability, chemotaxis, direct bacterial cell lysis, and histamine release.

• Cardinal Signs and Clinical Manifestations:

  • Local Effects:

  • Redness (Rubor) and Warmth (Calor): Caused by hyperemic arteriolar vasodilation.

  • Swelling (Tumor/Edema): Caused by protein-rich exudate accumulation in the extravascular space.

  • Pain (Dolor): Caused by increased interstitial pressure compressing nerves and direct stimulation by bradykinin and prostaglandins.

  • Loss of Function (Functio Laesa): Secondary to tissue swelling, pain, and cellular damage.

• Types of Inflammatory Exudate:

  • Serous Exudate: Watery fluid containing minimal protein and white blood cells (e.g., fluid inside allergic skin blisters or thermal burns).

  • Fibrinous Exudate: Thick, sticky exudate high in fibrin and cellular content; increases risk of scar adhesion.

  • Purulent Exudate: Thick, yellow-green exudate rich in leukocytes, necrotic cell debris, and dead/living microorganisms (pus). Abscess = localized accumulation of purulent exudate within solid tissue.

  • Hemorrhagic Exudate: Sanguineous exudate containing red blood cells, indicating microvascular rupture.

• Systemic Effects:

  • Mild Pyrexia (Fever): Initiated by endogenous pyrogen release from white blood cells.

  • Malaise: Overall generalized feeling of physical discomfort and weakness.

  • Fatigue and Lethargy.

  • Anorexia (Loss of appetite).

  • Headache.

  • Physiology of Fever Development:

• Release of circulating endogenous pyrogens (interleukins, TNF) into blood.

• Pyrogens action on hypothalamic regulatory centers resets body core thermostat to a higher target level.

• Chills phase (Heat-generating responses): Cutaneous vasoconstriction (pallor and cold skin), shivering skeletal muscle contractions, increased basal metabolic rate (BMR), increased heart rate, and curling up.

• Fever reach phase: Body temperature climbs to the new target level; individual feels warm.

• Pyrogen elimination or antipyretic administration resets hypothalamic thermostat back to normal level ($37^\circ\text{C}$ / $98.6^\circ\text{F}$).

• Flush phase (Heat-loss responses): Cutaneous vasodilation (flushed skin), diaphoresis (sweating), lethargy, extending body.

• Normal body temperature restored.

• Diagnostic Blood Changes in Inflammation:

  • Leukocytosis: Elevated total WBC count ($>10{,}000\,\text{cells/mm}^3$), predominantly immature neutrophils ("shift to the left").

  • Differential Count: Shift in leukocyte sub-population distribution (e.g., bacterial infection increases neutrophils; viral infection increases lymphocytes; allergic response elevates eosinophils).

  • Elevated Plasma Proteins: Hepatic upregulation of acute-phase reactants (fibrinogen, prothrombin).

  • Elevated C-Reactive Protein (CRP): An acute-phase inflammatory biomarker synthesized by the liver; elevated within $24\text{--}48\,\text{hours}$ of acute tissue injury/necrosis.

  • Increased Erythrocyte Sedimentation Rate (ESR): High plasma protein levels bind red blood cells (rouleaux formation), causing them to settle faster in anticoagulated blood tubes.

  • Elevated Cell Enzymes: Leakage of tissue-specific enzymes from necrotic cells into circulation (e.g., AST/ALT in liver damage, troponin/CK-MB in cardiac damage).

• Chronic Inflammation:

  • Characteristics: Follows unresolved acute inflammation or repeated low-grade tissue injury.

  • Pathological Features: Less pronounced edema and exudate; extensive infiltration by mononuclear cells (lymphocytes, macrophages, plasma cells) and fibroblasts; continuous tissue destruction and fibrous scar formation.

  • Granuloma: A nodular collection of epithelioid macrophages surrounding un-digestible foreign material or micro-organisms (e.g., Mycobacterium tuberculosis).

• Pharmacological Management of Inflammation:

  • Acetylsalicylic Acid (ASA / Aspirin): Anti-inflammatory YES; Analgesic YES; Antipyretic YES. Risks: Delays blood clotting via platelet inhibition, causes GI distress, stomach ulceration, and allergic hypersensitivity.

  • Acetaminophen (Tylenol): Anti-inflammatory NO; Analgesic YES; Antipyretic YES. Risks: Hepatotoxicity at excessive doses; lacks anti-inflammatory or anti-platelet activity.

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs / Ibuprofen, Naproxen): Anti-inflammatory YES; Analgesic YES; Antipyretic YES. Risks: Gastric ulceration, GI bleeding, altered platelet aggregation, and potential renal toxicity.

  • Glucocorticoids (Corticosteroids / Prednisone, Dexamethasone): Anti-inflammatory YES; Analgesic NO; Antipyretic NO. Risks: Increases infection risk, lymphoid atrophy, catabolic tissue breakdown, delayed wound healing, osteoporosis, hypertension, edema, sodium/water retention, and hyperglycemia.

  • COX-2 Inhibitors (Celecoxib): Anti-inflammatory YES; Analgesic YES; Antipyretic NO. Risks: Minimal GI distress compared to NSAIDs; potential risk of myocardial infarction (MI) or cerebrovascular accident (CVA).

• Non-Pharmacological First Aid Therapy (RICE):

  • Rest: Minimizes further tissue displacement and injury.

  • Ice: Induces localized vasoconstriction, diminishing edema and acute hemorrhage.

  • Compression: Increases interstitial hydrostatic pressure to reduce fluid exudation.

  • Elevation: Enhances venous and lymphatic drainage away from damaged tissue.

Wound Healing, Tissue Repair, and Scarring

• Types of Tissue Repair:

  • Resolution: Minimal tissue damage; injured cells recover fully and return to normal structure/function within a brief timeframe (e.g., mild sunburn).

  • Regeneration: Damaged specialized tissue is replaced by identical, functional parenchymal cells via mitotic proliferation (e.g., hepatic cellular regeneration).

  • Replacement / Fibrosis: Severe or non-regenerative tissue loss is replaced by dense fibrous connective scar tissue, resulting in loss of original specialized tissue function.

• Surgical Intention Healing Patterns:

  • First Intention (Primary Healing):

  • Occurs in clean, uninfected wounds with closely approximated surgical edges (e.g., sutured incision).

  • Stepwise Process: Minimal tissue destruction -> Blood clot formation -> Infiltration by neutrophils -> Granulation tissue formation with capillary sprouting and fibroblast influx -> Epithelial re-surfacing -> Minimal fibrous scar.

  • Second Intention (Secondary Healing):

  • Occurs in large, gaping wounds with extensive tissue loss, irregular margins, or secondary infection.

  • Stepwise Process: Deep tissue defect fills with blood clot -> Prolonged inflammatory phase -> Large volume of granulation tissue bridges defect -> Epithelial migration over surface -> Myofibroblast contraction -> Formation of a large, dense scar.

• Complications of Scar Tissue Formation:

  • Loss of Function: Specialized cells (hair follicles, sensory nerve receptors, sweat glands) are absent in fibrotic scar tissue.

  • Contractures and Structural Obstructions: Non-elastic collagen fibers shorten over time, restricting joint motion or constricting internal hollow organ lumens (e.g., esophageal or intestinal strictures).

  • Adhesions: Bands of scar tissue that abnormally connect adjacent serosal surfaces or visceral organs, causing chronic pain or mechanical bowel obstruction.

  • Hypertrophic Scar / Keloid Formation: Uncontrolled overgrowth of dense collagen fibers extending beyond original injury boundaries, creating raised, firm skin masses.

  • Ulceration: Poorly vascularized scar tissue breaks down under physical stress or ischemia, leading to chronic non-healing tissue ulcers.

Pathophysiology and Management of Burns

• Etiology of Thermal and Non-Thermal Burns:

  • Thermal Injuries: Open flames, hot liquids (scalds), direct contact with superheated objects.

  • Chemical Injuries: Strong acids, alkaline substances, corrosive solvents.

  • Radiation Injuries: Ultraviolet exposure (sunburn), therapeutic oncological radiation.

  • Electrical Injuries: High-voltage passage causing internal pathway thermal necrosis, cardiac dysrhythmias.

  • Light and Friction Injuries.

• Depth Classification of Burn Injuries:

  • Superficial Partial-Thickness (1st Degree):

  • Involves the epidermis and superficial dermis.

  • Clinical Signs: Erythema (redness), localized pain, mild edema, minimal to no blistering.

  • Healing: Complete recovery without scarring.

  • Deep Partial-Thickness (2nd Degree):

  • Destroys the epidermis and variable portions of the dermis.

  • Clinical Signs: Fluid-filled blister formation, weeping, red/edematous base, intense hyperalgesia.

  • Healing: Re-epithelialization from dermal appendages; variable scar formation.

  • Full-Thickness (3rd and 4th Degree):

  • Complete destruction of epidermis, dermis, dermal appendages, and underlying subcutaneous, muscle, or bone tissue.

  • Clinical Signs: Hard, dry, leathery eschar; insensate (painless center due to nerve destruction); charred or porcelain-white appearance.

  • Healing: Requires debridement, surgical excision, and skin grafting; extensive scarring and contracture formation.

• Estimation of Total Body Surface Area (BSA) - Rule of Nines:

  • Total Head: $9\%$ (Anterior $4.5\%$, Posterior $4.5\%$

  • Upper Extremities (Two Arms): $18\%$ Total (Each arm = $9\%$ total: Anterior $4.5\%$, Posterior $4.5\%$

  • Trunk (Torso): $36\%$ Total (Anterior $18\%$ [Chest $9\%$, Abdomen $9\%$], Posterior $18\%$

  • Perineum: $1\%$

  • Lower Extremities (Two Legs): $36\%$ Total (Each leg = $18\%$ total: Anterior $9\%$ [Thigh $4.5\%$, Lower leg $4.5\%$], Posterior $9\%$

  • Total Body Surface Area sum: $100\%$

• Systemic Complications and Management of Severe Burns:

  • Massive Hypovolemic Shock and Dehydration: Capillary permeability causes fluid, electrolyte, and protein leakage into interstitial space, causing severe hypovolemia and hemoconcentration.

  • Respiratory Complications: Inhalation of superheated air, steam, or toxic combustion byproducts leads to airway edema, broncho-constriction, alveolar damage, and acute respiratory distress syndrome (ARDS).

  • Hyper-metabolism: Sustained catabolic state requiring massive nutritional caloric intake.

  • Infection and Sepsis: Loss of primary skin barrier combined with protein exudate provides an environment for opportunistic bacterial pathogens (Pseudomonas aeruginosa, Staphylococcus aureus).

  • Therapeutic Interventions: Immediate fluid resuscitation, wound debridement, infection prevention, skin grafting, physical/occupational therapy, and surgical release of scarring contractures.

Autoimmune Disorders: Systemic Lupus Erythematosus (SLE)

• Etiology and Pathophysiology:

  • Pathophysiology: Multisystem autoimmune connective tissue disease characterized by chronic tissue and organ inflammation.

  • Disease Trajectory: Characterized by active disease flare-ups alternating with periods of remission.

  • Immune Mechanism: Auto-antibodies (primarily Anti-Nuclear Antibodies [ANA] and Anti-double stranded DNA [anti-dsDNA]) target cellular nuclear materials, forming circulating immune complexes that deposit in small blood vessels, joints, kidneys, and tissues (Type III Hypersensitivity).

• Predisposing Risk Factors and Demographics:

  • Biological Sex: Predominantly affects females ($9:1$ female-to-male ratio during reproductive years).

  • Demographics: Highest prevalence and clinical severity observed in young African American females.

  • Contributing Factors: Interactions between sex hormones (estrogen), genetic predisposition, and environmental triggers (UV light exposure, physical/emotional stress, viral infections).

• Diagnostic Laboratory Biomarkers and Testing:

  • Positive Antinuclear Antibody (ANA) Test: Highly sensitive screening test (High titer).

  • Anti-double-stranded DNA (anti-dsDNA) Antibody: Specific diagnostic biomarker (High level during active flares).

  • Anti-Sm (Anti-Smith) Antibody: Highly specific diagnostic auto-antibody.

  • Serum Complement Levels ($C_3$, $C_4$): Low/Decreased levels due to complement consumption by circulating immune complexes.

  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Elevated levels during disease flares.

  • Complete Blood Count (CBC): Cytopenias including leukopenia (low WBCs), anemia (low RBCs secondary to autoimmune hemolytic anemia), and thrombocytopenia (low platelets).

  • Lactate Dehydrogenase (LDH): Elevated due to tissue injury and hemolysis.

  • Renal Panel and Urinalysis: Elevated Blood Urea Nitrogen (BUN), elevated serum creatinine, proteinuria ($2+$ or greater), and cellular casts indicating Lupus Nephritis.

  • Diagnostic Skin Biopsy: Confirms immune complex deposition at the dermal-epidermal junction.

• Clinical Signs and Symptoms (Cues):

  • Dermatological / Mucocutaneous:

  • Erythematous butterfly (malar) rash over the nasal bridge and cheeks.

  • Photosensitivity (severe cutaneous eruption upon sunlight exposure).

  • Alopecia (hair loss).

  • Painless oral/mucosal ulcerations.

  • Musculoskeletal: Polyarthritis, symmetric arthralgia, joint inflammation without erosive bony changes.

  • Cardiopulmonary: Pericarditis, pleuritis, chest pain, dyspnea, vasculitis, vasospasms (Raynaud phenomenon), heart murmur, and secondary heart failure.

  • Renal: Lupus Nephritis leading to proteinuria, hypertension, renal failure, and systemic fluid retention.

  • Neurological / Central Nervous System: Brain fog, cognitive impairment, chronic headaches, mood swings, and neuropsychiatric events.

  • Systemic Symptoms: Severe chronic fatigue, low-grade fevers, lymphadenopathy, and tissue necrosis secondary to chronic inflammatory vasculitis.

• Therapeutic Interventions and Disease Management:

  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Controls mild joint pain and serositis.

  • Antimalarials (Hydroxychloroquine): Disease-modifying agent reducing flare frequency and dermatological manifestations.

  • Glucocorticoids (Prednisone): Controls acute severe inflammatory flares.

  • Immunosuppressive Therapies (Azathioprine, Mycophenolate Mofetil, Cyclophosphamide): Inhibits auto-antibody production in organ-threatening disease.

  • Preventive Interventions: Rigorous photoprotection (sunscreen, sun avoidance), stress management, smoking cessation, good sleep hygiene, routine health monitoring, and annual influenza vaccination.

Immunodeficiency Disorders: Human Immunodeficiency Virus (HIV) and AIDS

• Pathophysiology and Viral Dynamics:

  • Pathogen: Human Immunodeficiency Virus (HIV), an enveloped retrovirus.

  • Target Host Cells: Cells expressing surface $CD4^+$ receptors, primarily helper $T$ lymphocytes ($CD4^+$ $T$ cells), macrophages, and dendritic cells.

  • Functional Role of $CD4^+$ Helper $T$ Cells: Coordinate immune activation by secreting cytokines (chemical messengers) to activate cytotoxic $T$ cells, $B$ cells, and macrophages.

  • Mechanisms of Immune Depletion: HIV infection induces progressive destruction and loss of $CD4^+$ helper $T$ cells, causing collapse of cell-mediated adaptive immunity.

  • AIDS Definition: Acquired Immunodeficiency Syndrome is diagnosed when the $CD4^+$ $T$-cell count drops below 200\,\text{cells/\mu L} or when an individual develops AIDS-defining opportunistic infections (OIs) or malignancies.

• The Replication Life Cycle of HIV:

  1. Attachment (Binding): Viral envelope glycoprotein ($gp120$) binds to host $CD4^+$ receptor and co-receptors ($CCR5$ / $CXCR4$).

  2. Fusion: Viral envelope fuses with host cellular membrane, releasing viral capsid into cytoplasm.

  3. Reverse Transcription: Viral enzyme reverse transcriptase converts single-stranded viral RNA into double-stranded proviral DNA.

  4. Integration: Viral enzyme integrase inserts proviral DNA into host cell genomic DNA.

  5. Replication (Transcription/Translation): Host cellular machinery transcribes viral DNA into mRNA and translates structural proteins.

  6. Assembly: Immature viral RNA and proteins gather near the cellular membrane.

  7. Budding: Immature virions exit host membrane, taking a segment of host lipid envelope.

  8. Maturation: Viral enzyme protease cleaves protein chains, yielding infectious virions.

• Diagnostic Testing and Timeline:

  • Nucleic Acid Test (NAT): Detects viral RNA; confirms infection early (approx. $10\,\text{days}$ post-exposure). Quantifies viral load.

  • Combination Antigen/Antibody Test: Measures HIV $p24$ antigen and HIV antibodies; detects infection at approx. $2\,\text{weeks}$.

  • HIV Antibody Test (ELISA): Initial screening test; detects specific antibodies at $2\text{--}12\,\text{weeks}$.

  • Western Blot Test: Confirmatory test used following a positive initial ELISA screening test to verify anti-HIV antibodies.

  • Follow-up Monitoring Labs:

  • $CD4^+$ $T$-Cell Count: Monitors overall cellular immunocompetence.

  • Plasma HIV RNA (Viral Load): Assesses rate of viral replication and efficacy of antiretroviral therapy (ART).

  • Complete Blood Count (CBC): Evaluates for infection-induced leukocytosis during acute phase or secondary cytopenias.

• Clinical Stages and Manifestations:

  • Acute HIV Infection (Flu-like / Mononucleosis-like syndrome within $2\text{--}4\,\text{weeks}$ post-exposure):

  • Generalized fever, chills, night sweats.

  • Diffuse erythematous maculopapular rash.

  • Generalized lymphadenopathy (swollen lymph nodes).

  • Myalgias, arthralgia, severe fatigue.

  • Sore throat (pharyngitis), headache.

  • Gastrointestinal upset (nausea, diarrhea).

  • Chronic Latent Phase: Asymptomatic or mild persistent lymphadenopathy; progressive decrease in $CD4^+$ count.

  • Acquired Immunodeficiency Syndrome (AIDS Stage):

  • Opportunistic Infections: Oral Candidiasis (thrush), Pneumocystis jirovecii pneumonia (PCP—a leading cause of pulmonary mortality in AIDS patients), Mycobacterium tuberculosis, Cytomegalovirus (CMV), Toxoplasmosis.

  • Opportunistic Malignancies: Kaposi's Sarcoma (raised, purplish-brown skin and mucosal lesions caused by HHV-8), Primary CNS Lymphoma, Non-Hodgkin Lymphoma.

  • Systemic Complications: AIDS wasting syndrome, HIV-associated dementia.

• Pharmacotherapy, Prevention, and Occupational Safety:

  • Combination Antiretroviral Therapy (ART): Suppresses viral replication, restores $CD4^+$ counts, prevents transmission, and halts progression to AIDS.

  • Transmission Pathways: Unprotected sexual contact, blood transfusions, shared contaminated needles (IV drug use), occupational needlestick accidents, and perinatal transmission (in utero, intrapartum, breastfeeding).

  • Occupational Safety Protocols for Healthcare Workers:

  • Adherence to standard precautions.

  • Consistent use of personal protective equipment (PPE).

  • Immediate washing of skin/mucous membranes exposed to blood or body fluids.

  • Utilizing engineered needle safety devices and avoiding recapping needles.

Practice Questions & Clinical Scenarios

• Question 1: A nurse in a clinic is assessing a client who has AIDS and a significantly decreased $CD4^+$ T-cell count. The nurse should recognize that the client is at risk for developing which of the following infectious oral conditions?

  • A. Halitosis

  • B. Gingivitis

  • C. Xerostomia

  • D. Candidiasis

  • Correct Answer: D

  • Rationale: Oral candidiasis (thrush) is an opportunistic fungal infection that frequently affects immunocompromised patients, such as those with AIDS and severe $CD4^+$ T-cell depletion. Halitosis is non-infectious, gingivitis is caused by dental plaque, and xerostomia is a drug side effect.

• Question 2: A couple is planning to have a child. The husband is a carrier of an autosomal recessive disorder, and the wife is unaffected (non-carrier). What is the probability that their child will inherit the disorder?

  • A. $0\%$

  • B. $25\%$

  • C. $50\%$

  • D. $100\%$

  • Correct Answer: A

  • Rationale: For an autosomal recessive disorder to be expressed, an offspring must inherit two copies of the mutated gene (one from each parent). Since the mother is completely unaffected and non-carrier ($TT$), she will always contribute a normal allele. Thus, the child has a $0\%$ chance of having the disease (though there is a $50\%$ chance of being an asymptomatic carrier).

• Question 3: Which of the following is a typical characteristic of autosomal recessive inheritance?

  • A. Affected individuals often have unaffected parents.

  • B. Disorder is passed directly from an affected parent to their child.

  • C. Males are more frequently affected than females.

  • D. One copy of the mutated gene is sufficient to cause the disorder.

  • Correct Answer: A

  • Rationale: Because heteroyzgous parents are asymptomatic carriers, children with autosomal recessive disorders are frequently born to unaffected carrier parents.

• Question 4: In a family with a history of cystic fibrosis (an autosomal recessive disorder), a child is diagnosed with the condition. What does this suggest about the genetic status of the parents?

  • A. Both parents are carriers.

  • B. One parent is affected, the other is a carrier.

  • C. One parent is a carrier, and the other is unaffected.

  • D. Both parents are affected.

  • Correct Answer: A

  • Rationale: Cystic fibrosis is autosomal recessive; both parents must contribute one mutated allele for the child to express the disease ($tt$).

• Question 5: A nurse is caring for a family with a male child diagnosed with an X-linked recessive disorder. The mother is a known carrier, and the father is unaffected. The couple is planning to have another child and asks about the risk of the new child inheriting the disorder. Which explanation should the nurse provide?

  • A. Male children have a $50\%$ chance of being affected because they inherit their X chromosome from their mother, while female children can be carriers if they inherit one affected X chromosome.

  • B. Both male and female children have an equal $50\%$ chance of inheriting the disorder since both parents contribute equally to the genetic risk.

  • C. Female children will be affected if they inherit one affected X chromosome from either parent, while male children cannot inherit the disorder from their mother.

  • D. Since the father is unaffected, there is no risk of any child inheriting the disorder regardless of the mother's carrier status.

  • Correct Answer: A

  • Rationale: Males inherit their single X chromosome from their mother ($X^r Y$); thus, sons of a carrier mother have a $50\%$ chance of disease. Daughters inherit the unaffected X from the father, so they have a $50\%$ chance of being carriers.

• Question 6: A nurse is caring for a couple where one parent has an autosomal dominant disorder, Marfan syndrome. The couple asks about the likelihood of their child inheriting the disorder and the implications if the child inherits both mutated alleles. How should the nurse respond?

  • A. The child has a $50\%$ chance of inheriting Marfan syndrome if one parent is affected, and inheriting two mutated alleles is rare but typically lethal in the neonatal period.

  • B. The child will inherit Marfan syndrome only if both parents carry the mutated gene; otherwise, there is no risk.

  • C. Since Marfan syndrome is autosomal dominant, the child has a $25\%$ chance of inheriting the disorder and $75\%$ chance of being unaffected.

  • D. The child has an equal chance of inheriting the disorder regardless of whether the parent is affected, as Marfan syndrome is influenced more by environmental factors.

  • Correct Answer: A

  • Rationale: Autosomal dominant disorders require only one mutant allele ($50\%$ inheritance risk per pregnancy). Homozygosity ($MM$) is rare and usually neonatal lethal.

• Question 7: A $25$-year-old patient presents with persistent flu-like symptoms. Which initial test should the nurse prioritize to confirm an HIV diagnosis?

  • A. Western blot test

  • B. ELISA test

  • C. CD4 count

  • D. Viral load test

  • Correct Answer: B

  • Rationale: The ELISA (or combination Ag/Ab test) is the standard initial screening tool for HIV.

• Question 8: After a positive ELISA test, what is the next step in confirming an HIV diagnosis?

  • A. Repeat the ELISA test

  • B. Perform a Western blot test

  • C. Conduct a CD4 count

  • D. Measure the viral load

  • Correct Answer: B

  • Rationale: A Western blot test is performed as a confirmatory test following a positive initial ELISA screening result.

• Question 9: A client with a positive ELISA test result is anxious about next steps. What should the nurse explain as the purpose of the Western blot test?

  • A. To assess viral load in the blood.

  • B. To confirm the presence of HIV antibodies.

  • C. To determine the CD4+ count.

  • D. To evaluate the progression of HIV to AIDS.

  • Correct Answer: B

  • Rationale: The Western blot confirms the specific presence of anti-HIV antibodies in serum.

• Question 10: A nurse in a provider's office is assessing a client who has AIDS. The nurse notes that the client has multiple and widespread raised, purplish-brown skin lesions. The nurse should recognize that these findings indicate which condition?

  • A. Actinic keratosis

  • B. Kaposi's sarcoma

  • C. Toxic epidermal necrolysis

  • D. Basal cell carcinoma

  • Correct Answer: B

  • Rationale: Kaposi's sarcoma is an AIDS-defining opportunistic vascular malignancy producing purplish-brown raised cutaneous lesions.

• Question 11: Which respiratory complication is commonly a cause of death in patients with AIDS?

  • A. Pneumocystis pneumonia (PCP)

  • B. Tuberculosis

  • C. Asthma

  • D. Chronic obstructive pulmonary disease (COPD)

  • Correct Answer: A

  • Rationale: Pneumocystis jirovecii pneumonia (PCP) is a major opportunistic infection causing severe pulmonary morbidity and death in AIDS patients.

• Question 12: Which of the following actions by healthcare workers can reduce the risk of occupational exposure to HIV? (Select all that apply)

  • Wearing personal protective equipment (PPE).

  • Washing hands/skin immediately after blood or fluid contact.

  • Utilizing engineered safety needle devices.

  • Avoiding recapping needles.

  • Correct Answer: All listed safety interventions reduce exposure risk.

• Question 13: A nurse is evaluating a client for HIV risk. Which of the following are valid risk factors that should be considered? (Select all that apply)

  • Perinatal exposure.

  • Intravenous drug use with shared needles.

  • Unprotected sexual intercourse.

  • Occupational needle stick accidents.

  • Correct Answer: All options listed represent true HIV transmission modes.

• Question 14: A patient with systemic lupus erythematosus (SLE) is experiencing a flare-up. Which laboratory finding is most indicative of increased disease activity?

  • A. Elevated C-reactive protein (CRP)

  • B. Decreased erythrocyte sedimentation rate (ESR)

  • C. Increased hemoglobin levels

  • D. Decreased white blood cell count

  • Correct Answer: A

  • Rationale: Elevated CRP and ESR indicate active systemic inflammation during an SLE disease flare.

• Question 15: A patient presents with a WBC count of $15{,}000\,\text{cells/mm}^3$. Which of the following conditions does this most likely indicate?

  • A. Leukopenia

  • B. Leukocytosis

  • C. Thrombocytopenia

  • D. Anemia

  • Correct Answer: B

  • Rationale: Normal WBC count ranges from $4{,}000\text{--}10{,}000\,\text{cells/mm}^3$. A count of $15{,}000\,\text{cells/mm}^3$ represents leukocytosis.

• Question 16: What is the primary role of white blood cells in the body?

  • A. To transport oxygen

  • B. To aid in blood clotting

  • C. To fight infections

  • D. To regulate blood pressure

  • Correct Answer: C

  • Rationale: White blood cells (leukocytes) mediate immune defense against pathogens and foreign material.

• Question 17: A patient presents with a suspected allergic reaction. Which CBC finding would most likely support the diagnosis of an allergic reaction?

  • A. Increased neutrophils

  • B. Increased eosinophils

  • C. Decreased lymphocytes

  • D. Increased red blood cells

  • Correct Answer: B

  • Rationale: Eosinophils increase during allergic reactions and parasitic infestations.

• Question 18: A patient with systemic lupus erythematosus (SLE) presents with elevated blood urea nitrogen (BUN) and $2+$ urine protein. What is the most likely organ involvement?

  • A. Kidneys

  • B. Liver

  • C. Brain

  • D. Heart

  • Correct Answer: A

  • Rationale: Proteinuria and elevated BUN indicate renal involvement (Lupus Nephritis).

• Question 19: A nurse is planning interventions for a patient with SLE to minimize the risk of flare-ups. Which of the following strategies should be included? (Select all that apply)

  • Smoking cessation.

  • Stress management techniques.

  • Promoting good sleep hygiene.

  • Annual influenza vaccination.

  • Photoprotection (avoiding sunbathing).

  • Correct Answer: All listed lifestyle choices and preventive interventions lower SLE flare risks.

• Question 20: Which of the following symptoms are commonly associated with Systemic Lupus Erythematosus (SLE) that may impact daily activities? (Select all that apply)

  • Chronic severe fatigue.

  • Symmetrical joint pain (arthralgia).

  • Low-grade fevers.

  • Photosensitivity.

  • Correct Answer: These cues represent classical systemic manifestations of SLE.

• Question 21: Which of the following are initial symptoms of acute HIV infection?

  • Fever, cutaneous rash, night sweats, fatigue, myalgias, pharyngitis, and headache appearing $2\text{--}4\,\text{weeks}$ post-exposure.

• Question 22: Which patient demographic is most commonly associated with a higher risk of developing SLE?

  • A. Middle-aged Caucasian males

  • B. Young African American females

  • C. Elderly Asian males

  • D. Adolescent Hispanic males

  • Correct Answer: B

  • Rationale: SLE disproportionately affects young females, with highest incidence and severity in African American females.

• Question 23: Which of the following statements accurately describe the functions of cellular membranes?

  • Selective permeability regulating intracellular homeostasis, containing signal-transduction receptors, and releasing inflammatory chemical mediators upon disruption.

• Question 24: Which of the following chemical mediators is primarily responsible for causing the immediate pain, redness, and swelling associated with acute inflammation?

  • A. Histamine

  • B. Prostaglandin

  • C. Arachidonic acid

  • D. Leukotrienes

  • Correct Answer: A

  • Rationale: Histamine released from mast cell granules causes rapid immediate vasodilation and increased capillary permeability.

• Question 25: A patient with Systemic Lupus Erythematosus (SLE) presents with decreased Hgb and Hct. Which physiological process is most likely contributing to this finding?

  • A. Increased destruction of red blood cells due to hemolytic anemia.

  • B. Increased production of red blood cells.

  • C. Decreased production of white blood cells.

  • D. Fluid retention causing dilutional anemia.

  • Correct Answer: A

  • Rationale: SLE causes autoimmune destruction of erythrocytes via type II autoantibody-mediated hemolytic anemia.

• Question 26: A patient experiences a rash and difficulty breathing after being administered penicillin. Which type of hypersensitivity reaction is most likely occurring?

  • A. Type I (Immediate) Hypersensitivity

  • B. Type II (Cytotoxic) Hypersensitivity

  • C. Type III (Immune Complex) Hypersensitivity

  • D. Type IV (Delayed) Hypersensitivity

  • Correct Answer: A

  • Rationale: IgE-mediated mast cell degranulation triggering acute bronchospasm and urticaria represents Type I immediate hypersensitivity.

• The cell is the basic unit of all living organisms, with approximately 37 trillion cells and over 200 distinct types in the human body, averaging 10-30 µm in diameter. Neurons are the longest cells.

• Lifespan varies: White blood cells last hours to days; skin cells renew every 2-3 weeks, red blood cells circulate for about 120 days, and brain neurons can last a lifetime.

• Cellular functions include red blood cell production in the bone marrow and signaling with biochemical signals essential for coordination and apoptosis, which removes unnecessary cells.

• Key structures:

  • Cell Membrane: Selectively permeable, maintains homeostasis, and facilitates signaling.

  • Nucleus: Directs activity and houses DNA.

  • Cytoplasm: Site of metabolic reactions.

  • Ribosomes: Protein synthesis.

  • Endoplasmic Reticulum: Rough synthesizes proteins; smooth synthesizes lipids.

  • Mitochondria: ATP generation.

  • Golgi Complex: Modifies and packages proteins.

  • Lysosomes: Digestive enzymes for waste and debris.

• Genetics: Genes are heredity units, with 23 chromosome pairs in humans. Disorders can be dominant, recessive, X-linked, multifactorial, or chromosomal abnormalities. Punnett squares help predict inheritance.

• Immune System: Three lines of defense include physical barriers, phagocytosis, and adaptive immunity. White blood cells (leukocytes) and antibodies play crucial roles in fighting infections.

• Inflammation: A protective response characterized by redness, swelling, pain, and loss of function, mediated by various substances, including histamines and cytokines.

• Wound Healing: Involves resolution, regeneration, or replacement with scar tissue.

• Burns: Classified by depth, with varying degrees of severity and healing processes. The Rule of Nines estimates total body surface area affected.

• Autoimmunity: Diseases like Systemic Lupus Erythematosus (SLE) involve chronic inflammation and auto-antibody production, significantly affecting demographics and requiring specific diagnostic markers.

Signs and Symptoms of Lupus

• Dermatological / Mucocutaneous:

  • Erythematous butterfly rash over the cheeks and nose.

  • Photosensitivity (rash from sunlight).

  • Alopecia (hair loss).

  • Oral/mucosal ulcerations.

• Musculoskeletal:

  • Polyarthritis, symmetric joint pain without erosive bony changes.

• Cardiopulmonary:

  • Pericarditis, pleuritis, chest pain, dyspnea.

  • Vasculitis or Raynaud phenomenon, secondary heart failure.

• Renal:

  • Lupus Nephritis leading to proteinuria, hypertension, renal failure.

• Neurological / Central Nervous System:

  • Brain fog, cognitive impairment, mood swings, chronic headaches.

• Systemic Symptoms:

  • Chronic fatigue, low-grade fever, lymphadenopathy, and tissue necrosis.

Pathology of Lupus

• Etiology:

  • Multisystem autoimmune disorder leading to chronic tissue inflammation.

  • Auto-antibodies target cellular nuclear materials, forming immune complexes that deposit in tissues.

• Autoimmunity Mechanism:

  • Antinuclear antibodies (ANA) and anti-double stranded DNA antibodies contribute to inflammation and organ damage.   

Rationales for Symptoms

• Inflammation of joints and tissues leads to pain and swelling.

• Deposits of immune complexes in the kidneys cause nephritis.

• Light sensitivity leads to dermal responses, like rashes.

Treatment Options

• NSAIDs:

  • Reduce mild joint pain and inflammation.

• Antimalarials (Hydroxychloroquine):

  • Modulate immune response and decrease flare frequency.

• Glucocorticoids (Prednisone):

  • Control severe inflammatory flares.

• Immunosuppressive Therapies:

  • (e.g., Azathioprine, Cyclophosphamide) for severe organ-threatening manifestations.   

Diagnostic Laboratory Biomarkers and Testing

• Positive ANA Test:

  • Screening tool for autoantibodies.

• Anti-double-stranded DNA Antibodies:

  • Indicators of disease activity.

• Anti-Sm Antibodies:

  • Specific to lupus diagnosis.

• Complement Levels (C3, C4):

  • Often decreased in active disease due to consumption by immune complexes.

• CBC:

  • May show cytopenias, including leukopenia and anemia.

• Elevated BUN and creatinine:

  • Indicate renal involvement (lupus nephritis).

• Urinalysis:

  • Detects proteinuria and cellular casts indicating renal impairment.

Summary

Lupus presents with a spectrum of symptoms affecting various organ systems due to its autoimmune nature, requiring comprehensive diagnostic and treatment approaches, focusing on symptom management and preventing flares.

Signs and Symptoms of HIV/AIDS

• Acute HIV Infection (Flu-like/Mnonucleosis-like symptoms within 2-4 weeks post-exposure):

  • Generalized fever, chills, night sweats.

  • Diffuse erythematous maculopapular rash.

  • Generalized lymphadenopathy (swollen lymph nodes).

  • Myalgias, arthralgia, severe fatigue.

  • Sore throat (pharyngitis), headache.

• Chronic Latent Phase:

  • Asymptomatic or mild persistent lymphadenopathy; progressive decrease in CD4+ count.

• Acquired Immunodeficiency Syndrome (AIDS Stage):

  • Opportunistic Infections:

  • Oral Candidiasis (thrush), Pneumocystis jirovecii pneumonia (PCP), Mycobacterium tuberculosis, Cytomegalovirus (CMV), Toxoplasmosis.

  • Opportunistic Malignancies:

  • Kaposi's Sarcoma, Primary CNS Lymphoma, Non-Hodgkin Lymphoma.

  • Systemic Complications:

  • AIDS wasting syndrome, HIV-associated dementia.

Pathophysiology and Viral Dynamics

• Pathogen: Human Immunodeficiency Virus (HIV), an enveloped retrovirus.

• Target Host Cells: Cells expressing surface CD4+ receptors, primarily helper T lymphocytes (CD4+ T cells), macrophages, and dendritic cells.

• Functional Role of CD4+ Helper T Cells: Coordinate immune activation by secreting cytokines to activate cytotoxic T cells, B cells, and macrophages.

• Mechanisms of Immune Depletion: HIV infection induces progressive destruction and loss of CD4+ helper T cells, causing collapse of cell-mediated adaptive immunity.

• AIDS Definition: Diagnosed when the CD4+ T-cell count drops below 200 cells/μL or when an individual develops AIDS-defining opportunistic infections (OIs) or malignancies.

The Replication Life Cycle of HIV

1. Attachment (Binding): Viral envelope glycoprotein (gp120) binds to host CD4+ receptor and co-receptors.

2. Fusion: Viral envelope fuses with host cellular membrane, releasing viral capsid.

3. Reverse Transcription: Viral enzyme reverse transcriptase converts single-stranded RNA into double-stranded proviral DNA.

4. Integration: Viral enzyme integrase inserts proviral DNA into host cell genomic DNA.

5. Replication (Transcription/Translation): Host cellular machinery transcribes viral DNA into mRNA and translates structural proteins.

6. Assembly: Immature viral RNA and proteins gather near the cellular membrane.

7. Budding: Immature virions exit host membrane, taking a segment of host lipid envelope.

8. Maturation: Viral enzyme protease cleaves protein chains, yielding infectious virions.

Diagnostic Testing and Timeline

• Nucleic Acid Test (NAT): Detects viral RNA; confirms infection early (approx. 10 days post-exposure). Quantifies viral load.

• Combination Antigen/Antibody Test: Measures HIV p24 antigen and antibodies; detects infection at approx. 2 weeks.

• HIV Antibody Test (ELISA): Initial screening; detects specific antibodies at 2-12 weeks.

• Western Blot Test: Confirmatory test following a positive initial ELISA screening.

Follow-up Monitoring Labs

• CD4+ T-Cell Count: Monitors overall cellular immunocompetence.

• Plasma HIV RNA (Viral Load): Assesses rate of viral replication and efficacy of antiretroviral therapy (ART).

• Complete Blood Count (CBC): Evaluates for infection-induced leukocytosis or secondary cytopenias.

Pharmacotherapy, Prevention, and Occupational Safety

• Combination Antiretroviral Therapy (ART): Suppresses viral replication, restores CD4+ counts, prevents transmission, and halts progression to AIDS.

• Transmission Pathways: Unprotected sexual contact, blood transfusions, shared contaminated needles, occupational needlestick accidents, and perinatal transmission.

• Occupational Safety Protocols for Healthcare Workers:
  
  

  • Adherence to standard precautions.

  • Consistent use of personal protective equipment (PPE).

  • Immediate washing of skin/mucous membranes exposed to blood or body fluids.

  • Utilizing engineered needle safety devices and avoiding recapping needles.